NASDAQ: DAWN
Day One Biopharmaceuticals Inc Stock

$7.19+0.19 (+2.71%)
Updated Jul 10, 2025
DAWN Price
$7.19
Fair Value Price
N/A
Market Cap
$728.80M
52 Week Low
$6.08
52 Week High
$16.76
P/E
-10.13x
P/B
1.52x
P/S
5.03x
PEG
N/A
Dividend Yield
N/A
Revenue
$161.92M
Earnings
-$69.08M
Gross Margin
95%
Operating Margin
-38.25%
Profit Margin
-42.7%
Debt to Equity
0.11
Operating Cash Flow
-$87M
Beta
0.76
Next Earnings
Aug 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A

DAWN Overview

Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with genetically defined cancers. Its lead product candidates are DAY101 and Pimasertib. Day One Biopharmaceuticals was incorporated in 2018 and is headquartered in South San Francisco, CA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine DAWN's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
DAWN
Ranked
#126 of 475

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important DAWN news, forecast changes, insider trades & much more!

DAWN News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DAWN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

DAWN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DAWN is good value based on its book value relative to its share price (1.52x), compared to the US Biotechnology industry average (4.7x)
P/B vs Industry Valuation
DAWN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DAWN due diligence checks available for Premium users.

Valuation

DAWN price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-10.13x
Industry
-162x
Market
30.8x

DAWN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.52x
Industry
4.7x
DAWN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

DAWN's financial health

Profit margin

Revenue
$30.8M
Net Income
-$36.0M
Profit Margin
-117%
DAWN's Earnings (EBIT) of -$61.94M... subscribe to Premium to read more.
Interest Coverage Financials
DAWN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$534.4M
Liabilities
$54.8M
Debt to equity
0.11
DAWN's short-term assets ($508.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DAWN's short-term assets ($508.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DAWN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$59.0M
Investing
-$32.6M
Financing
$0.0
DAWN's operating cash flow (-$87.38M)... subscribe to Premium to read more.
Debt Coverage Financials

DAWN vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
DAWNC$728.80M+2.71%-10.13x1.52x
IMTXD$729.30M+1.69%-35.50x1.21x
GYREC$732.25M-2.38%97.63x10.75x
MRVIF$735.97M+4.71%-2.54x2.45x
AVBPF$753.70M+3.23%-5.84x3.72x

Day One Biopharmaceuticals Stock FAQ

What is Day One Biopharmaceuticals's quote symbol?

(NASDAQ: DAWN) Day One Biopharmaceuticals trades on the NASDAQ under the ticker symbol DAWN. Day One Biopharmaceuticals stock quotes can also be displayed as NASDAQ: DAWN.

If you're new to stock investing, here's how to buy Day One Biopharmaceuticals stock.

What is the 52 week high and low for Day One Biopharmaceuticals (NASDAQ: DAWN)?

(NASDAQ: DAWN) Day One Biopharmaceuticals's 52-week high was $16.76, and its 52-week low was $6.08. It is currently -57.1% from its 52-week high and 18.26% from its 52-week low.

How much is Day One Biopharmaceuticals stock worth today?

(NASDAQ: DAWN) Day One Biopharmaceuticals currently has 101,362,468 outstanding shares. With Day One Biopharmaceuticals stock trading at $7.19 per share, the total value of Day One Biopharmaceuticals stock (market capitalization) is $728.80M.

Day One Biopharmaceuticals stock was originally listed at a price of $25.89 in May 27, 2021. If you had invested in Day One Biopharmaceuticals stock at $25.89, your return over the last 4 years would have been -72.23%, for an annualized return of -27.41% (not including any dividends or dividend reinvestments).

How much is Day One Biopharmaceuticals's stock price per share?

(NASDAQ: DAWN) Day One Biopharmaceuticals stock price per share is $7.19 today (as of Jul 10, 2025).

What is Day One Biopharmaceuticals's Market Cap?

(NASDAQ: DAWN) Day One Biopharmaceuticals's market cap is $728.80M, as of Jul 11, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Day One Biopharmaceuticals's market cap is calculated by multiplying DAWN's current stock price of $7.19 by DAWN's total outstanding shares of 101,362,468.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.